Side-by-side comparison of AI visibility scores, market position, and capabilities
Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match injectable semaglutide efficacy with once-daily oral dosing for obesity and type 2 diabetes.
Verdiva Bio is developing oral small molecule GLP-1 receptor agonists to compete in the massive weight loss and diabetes market dominated by injectable semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Current oral GLP-1 options like semaglutide tablets have low bioavailability and require fasting, while Verdiva's chemical series aims for significantly higher exposure matching injectable efficacy with a convenient once-daily pill taken without dietary restrictions.
SF YC W24 AI support agent builder at 80% resolution time reduction and 71% ticket deflection; $500K from a16z/Greylock/YC/Netflix competing with Intercom Fin for customer support AI workflow automation.
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 additional investors — providing customer support teams with an AI agent builder that translates existing support processes and workflows into predictable, reliable AI automation, achieving 80% reduction in resolution time and 71% ticket deflection for deployed teams. Founded in 2023 and targeting customer support leaders at growth-stage software companies, Duckie enables support teams to deploy AI agents in minutes without engineering dependency.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.